Alpha 2.0
Login Register
» Authors » Philip McCloud

Philip McCloud

Explore the profile of Philip McCloud including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 23
Citations 782
Followers 0
Related Specialties
Oncology
General Medicine
Radiology
Top 10 Co-Authors
Sandra Louw
Jeremy R A Paull
George R Kinghorn
Alex Castellarnau
Katherine Clark
Arthur S Waldbaum
Julie Hill
Christine F McDonald
David Currow
Belinda Fazekas
Published In
Asia Pac J Clin Oncol
J Med Imaging Radiat Oncol
BMJ Open
NEJM Evid
N Engl J Med
Affiliations
Soon will be listed here.
Recent Articles
1.
Differences in uni-dimensional breathlessness measures and thresholds for clinical response in a randomised controlled trial in people with chronic breathlessness: an exploratory study
Ferreira D, Ekstrom M, Louw S, McCloud P, Johnson M, Clark K, et al.
BMJ Open Respir Res . 2024 Dec; 11(1. PMID: 39632100
Introduction: Optimally measuring improvements in chronic breathlessness in clinical practice and research continues to evolve. The aim of this study was to consider the performance of uni-dimensional measures in ....
2.
Prescribed Water Intake in Autosomal Dominant Polycystic Kidney Disease
Rangan G, Wong A, Munt A, Zhang J, Saravanabavan S, Louw S, et al.
NEJM Evid . 2024 Feb; 1(1):EVIDoa2100021. PMID: 38319283
BACKGROUND: Arginine vasopressin promotes kidney cyst growth in autosomal dominant polycystic kidney disease (ADPKD). Increased water intake reduces arginine vasopressin and urine osmolality and may slow kidney cyst growth. METHODS:...
3.
Astodrimer sodium antiviral nasal spray for reducing respiratory infections is safe and well tolerated in a randomized controlled trial
Castellarnau A, Heery G, Seta A, Luscombe C, Kinghorn G, Button P, et al.
Sci Rep . 2022 Jun; 12(1):10210. PMID: 35715644
Astodrimer sodium is a dendrimer molecule with antiviral and virucidal activity against SARS-CoV-2 and other respiratory viruses in vitro, and has previously been shown to be safe and well tolerated,...
4.
A phase 3, randomized, controlled trial of Astodrimer 1% Gel for preventing recurrent bacterial vaginosis
Schwebke J, Carter B, Waldbaum A, Agnew K, Paull J, Price C, et al.
Eur J Obstet Gynecol Reprod Biol X . 2021 Feb; 10:100121. PMID: 33537666
Objective: The objective of the study was to confirm the efficacy and safety of Astodrimer 1% Gel to prevent recurrence of bacterial vaginosis. Study Design: 864 women with a diagnosis...
5.
Early impact of the Australian national shingles vaccination program with the herpes zoster live attenuated vaccine
Litt J, Booy R, Bourke D, Dwyer D, Leeb A, McCloud P, et al.
Hum Vaccin Immunother . 2020 May; 16(12):3081-3089. PMID: 32420793
Herpes zoster (shingles) is a painful condition resulting from reactivation of latent varicella zoster virus (VZV). The Australian National Shingles Vaccination Program (commenced November 2016) provides free herpes zoster vaccination...
6.
A phase 2, double-blind, multicenter, randomized, placebo-controlled, dose‑ranging study of the efficacy and safety of Astodrimer Gel for the treatment of bacterial vaginosis
Waldbaum A, Schwebke J, Paull J, Price C, Edmondson S, Castellarnau A, et al.
PLoS One . 2020 May; 15(5):e0232394. PMID: 32365097
Background: Astodrimer Gel contains a novel dendrimer intended to treat and prevent bacterial vaginosis. We assessed the efficacy and safety of Astodrimer Gel for treatment of bacterial vaginosis. Methods: 132...
7.
Two phase 3, double-blind, placebo-controlled studies of the efficacy and safety of Astodrimer 1% Gel for the treatment of bacterial vaginosis
Chavoustie S, Carter B, Waldbaum A, Donders G, Peters K, Schwebke J, et al.
Eur J Obstet Gynecol Reprod Biol . 2019 Dec; 245:13-18. PMID: 31812702
Objective: Astodrimer is a dendrimer formulated in a vaginal gel to treat bacterial vaginosis (BV) and prevent recurrence. The objective of these studies was to confirm the efficacy and safety...
8.
Controlled-Release Oxycodone vs. Placebo in the Treatment of Chronic Breathlessness-A Multisite Randomized Placebo Controlled Trial
Ferreira D, Louw S, McCloud P, Fazekas B, McDonald C, Agar M, et al.
J Pain Symptom Manage . 2019 Oct; 59(3):581-589. PMID: 31655189
Context: Chronic breathlessness is a clinical syndrome that results in significant distress and disability. Morphine can reduce chronic breathlessness when the contributing etiologies are optimally treated. Objectives: Does oxycodone reduce...
9.
Regular, sustained-release morphine for chronic breathlessness: a multicentre, double-blind, randomised, placebo-controlled trial
Currow D, Louw S, McCloud P, Fazekas B, Plummer J, McDonald C, et al.
Thorax . 2019 Sep; 75(1):50-56. PMID: 31558624
Introduction: Morphine may decrease the intensity of chronic breathlessness but data from a large randomised controlled trial (RCT) are lacking. This first, large, parallel-group trial aimed to test the efficacy...
10.
A simple algorithm to predict non-compliance with organ at risk dose-volume constraints when planning intensity modulated post-prostatectomy radiation treatment: 'Why we should put the CART before the horse'
Collier N, Kneebone A, Hruby G, McCloud P, Booth J, Eade T
J Med Imaging Radiat Oncol . 2019 May; 63(4):546-551. PMID: 31136089
Introduction: It is not always apparent when the optimal IMRT/VMAT plan for post-prostatectomy radiotherapy (PPRT) has been achieved. Individual variation in patient anatomy is a key contributor. This study aimed...